North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-02-01 Thyroid hormones
| Levothyroxine |
|
First Choice
|
|
 MHRA Drug Safety Update (May 2021): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products |
|
| Liothyronine |
|
Formulary
|
The most cost effective strength/formulation should be used
|
|
NHSE Liothyronine – advice for prescribers Items which should not routinely be prescribed in primary care |
|
| Levothyroxine |
|
Formulary
|
Solution for injection / infusion Approved only for patients with myxoedema coma. Not approved for routine replacement therapy. |
|
MHRA Drug Safety Update (May 2021): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products |
|
| Liothyronine Injection |
|
Formulary
|
|
|
Items which should not routinely be prescribed in primary care |
|
|
Links
- Items which should not routinely be prescribed in primary care
- Items which should not routinely be prescribed in primary care
- MHRA Drug Safety Update (May 2021): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
- MHRA Drug Safety Update (May 2021): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
- NHSE Liothyronine – advice for prescribers
- NICE NG132: Hyperparathyroidism (primary): diagnosis, assessment and initial management
- NICE NG145: Thyroid disease: assessment and management
- NTAG Endocrine System Recommendations